Publications by authors named "Isabel Massague"

Claim this Profile
S
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
Luis-Felipe Casado, José-Valentín García-Gutiérrez, Isabel Massagué, Pilar Giraldo, Manuel Pérez-Encinas

Cancer Med· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis